FDA Grants Breakthrough Therapy Designation for Acalabrutinib

August 1, 2017 – Today the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for acalabrutinib for the treatment of people with mantle cell lymphoma (MCL) who have received at least one prior therapy

While this news is for folks with mantle cell lymphoma, a cousin cancer to CLL, this is not an usual path to broader ultimate approval of a new medication.

Also, once a medication is approved, it can be used for any indication. though such “off label” insurance coverage can be a challenge

Overall, very good news

About the author

Todd Dennison

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to Venetoclax tablet Label
September 18, 2018

FDA Approval of Ibrutinib with Rituximab for Waldenström’s Macroglobulinemia
August 28, 2018

FDA Approval of Venetoclax in Combination with Rituximab (V+R) for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Who Have Received One Prior Therapy
June 9, 2018

FDA Approves Kymriah (tisagenlecleucel) for DLBCL
May 8, 2018

CLL Copay Assistance is NOW OPEN at the Leukemia & Lymphoma Society
April 17, 2018

FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
April 9, 2018